Sustained release formulation of pramipexole (Mirapex, Boehringer Ingelheim) outperforms its immediate release alternative to treat sleep disturbances in advanced Parkinson’s…
Articles by José Lopes, PhD
Prana Biotechnology’s investigational compound PBT434 prevented neuronal loss and improved motor function in an animal model of multiple…
Neupro patches (rotigotine) have been approved in China for treating symptoms of early-stage idiopathic (of unknown cause) Parkinson’s disease as a…
Herantis Pharma is launching a development program for non-invasive cerebral dopamine neurotrophic factor (CDNF) as a treatment candidate…
Xeomin (incobotulinumtoxinA) has been approved by the U.S. Food and Drug Administration to treat adults with chronic sialorrhea, or…
An investigative compound similar to those used to treat diabetes was able to slow Parkinson’s progression and ease behavioral symptoms…
Earlier disease onset and involuntary foot muscle contractions may be a consequence of mutations in the GCH1 gene in both Parkinson’s patients…
Visual hallucinations can be common in Parkinson’s patients and others with dementia, but the degree of distress they cause is greatly…
The U.S. Food and Drug Administration has approved a once-a-day capsule formulation and a lower tablet strength for Nuplazid…
Treatment with Gocovri (amantadine) reduced Parkinson’s dyskinesia — involuntary, jerky movements — and so-called “off” episodes, leading to longer…